← All trials
NCT03635021
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 15, 2018
- Primary completion
- Sep 15, 2021
- Completion date
- Sep 15, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 370
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)Lead sponsor
- AmgenCollaborator
- Hospital Universitario Ramon y CajalStudy chair
- Hospital Duran i ReynalsStudy chair
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.